Posted by Michael Wonder on 18 Feb 2020
ALX Oncology’s ALX148 receives two fast track designations from FDA for the treatment of patients with head and neck squamous cell carcinoma and patients with gastric or gastro-esophageal junction adenocarcinoma
18 February 2020 - ALX Oncology today announced that the U.S. FDA has granted two fast track designations for its lead candidate, ALX148, for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastro-esophageal junction (gastric/GEJ) carcinoma.
Data supporting these fast track designations were based on an open-label, multicenter Phase 1 clinical trial of ALX148 in combination with pembrolizumab or trastuzumab.
